Suzetrigine

Suzetrigine, also designated VX-548 with the CAS registry number 2649467-58-1, is an oral selective NaV1.8 inhibitor originally developed by Vertex Pharmaceuticals, marketed under the brand name Journavx and approved by the FDA for treating moderate to severe acute pain in adult patients. Its molecular formula is C₂₁H₂₀F₅N₃O₄ with a molecular weight of 473.4 g/mol. This chiral solid compound appears off-white to pale yellow, featuring a predicted boiling point of 591.8±50.0 °C and a density of 1.399±0.06 g/cm³. It exhibits limited solubility: slightly soluble in acetonitrile (0.1–1 mg/mL) and sparingly soluble in DMSO (1–10 mg/mL). As a voltage-gated sodium channel blocker, Suzetrigine targets NaV1.8 channels selectively expressed in peripheral nociceptors and dorsal root ganglia, which play a central role in pain signal transmission, delivering targeted analgesic effects by blocking pain signaling pathways without broad off-target sodium channel inhibition. Its full systematic chemical name, stereochemical configuration, InChIKey and SMILES structural string are available for synthetic, analytical and pharmaceutical research applications, making it a key reference compound for pain disorder mechanism studies and novel analgesic drug development.